Publisher: Institute of Oncology Ljubljana (Total: 1 journals)   [Sort alphabetically]

Showing 1 - 1 of 1 Journals sorted by number of followers
Onkologija     Open Access  
Similar Journals
Journal Cover
Onkologija
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1408-1741 - ISSN (Online) 1581-3215
Published by Institute of Oncology Ljubljana Homepage  [1 journal]
  • Oncologists' attitudes about sick leave in patients with breast
           cancer who are returning to work

    • Authors: Ivica Ratoša, Cvetka Grašič Kuhar
      Pages: 6 - 10
      Abstract: Background: Optimizing rehabilitation and return to work for patients with cancer is critical for both enhancing the well-being of this vulnerable population and decreasing social and financial costs on society as a whole. People who have survived cancer attempt to return to work and re-establish the former structure of their daily lives. In this article, we will look at oncologists' perspectives on sick leave for patients following breast cancer diagnosis.
      Methods: We conducted a small anonymous online survey on attitudes towards sick leave among Slovenian oncologists involved in the treatment of patients with breast cancer.
      Results: Twenty-four (46.2%) of 52 invited oncologists answered to the online survey, including 8 (33.3%) medical oncologists, 9 (37.5 %) radiation oncologists, and 7 (29.2%) surgeons. Oncologists' position, as measured on a 10-point Likert scale, is that communicating with patients and addressing their issues at return-to-work is a critical component of oncological care (average score 8.4/10). Simultaneously, they think that the ratio of time allocated to patients with breast cancer to time available for sick leave discussions during or after treatment is insufficient (average score 3.6/10). They experience "pressures" from patients regarding oppinion making for sick leave or disability retirement on a relatively frequent basis (average score 6.5/10). Additionally, the questionnaire included recommendations for the duration of sick leave, taking into account the nature and complexity of the therapy, as well as individual factors. It was proposed that a group of specialists will consitute a multidisciplinary board to evaluate patients on sick leave.
      Conculsion: When treating patients with cancer and determining their return to work, an individualized interdisciplinary approach is critical. The purpose of this study is to elicit oncologists' perspectives on the treatment of patients with breast cancer who are in an employment relationship, which will serve as a foundation for future research.
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
  • Gene therapy in oncology, first steps of development in Slovenia

    • Authors: Maja Čemažar, Tanja Jesenko, Maša Bošnjak, Boštjan Markelc, Urška Kamenšek, Simona Kranjc Brezar, Špela Kos, Urša Lampreht Tratar, Katarina Žnidar, Andrej Renčelj, Urška Matkovič, Teja Valant, Kristina Levpušček, Živa Modic, Tilen Komel, Tim Božič, Urša Kešar, Barbara Starešinič, Katja Uršič Valentinuzzi, Monika Savarin, Primož Strojan, Gorana Gašljević, Maja Ota, Aleš Grošelj, Črt Jamšek, Rosana Hudej, Matjaž Peterka, Frenk Smrekar, Barbara Hubad, Marjan Hosta, Jaka Kužnik, Lojze Hosta, Damijan Miklavčič, Matej Reberšek, Aleksandra Cvetkoska, Anja Zajc, Janja Dermol-Černe, Nataša Tozon, Nina Milevoj, Alenka Nemec Svete, Gregor Serša
      Pages: 12 - 21
      Abstract: Gene therapy is also attracting interest in oncology. Probably the most interesting approach is immunostimulation. Plasmid DNA can be constructed, which is coding for a specific immunostimulatory molecule, which is then delivered into the cells, either in tumour or normal tissue. The transfected tissue then becomes the producer of the molecules encoded in the plasmid. The product is then released from the cells, either locally or systemically into the bloodstream. Since plasmids have hampered transport through the plasma membrane, delivery systems are needed that are either viral or nonviral. In our studies we predominantly use the non-viral transfection system, based on electroporation of the cells.
      Interleukin 12 (IL-12) is a cytokine with well-known anti-tumour and anti-angiogenic function. Therefore, in the SmartGene.si project we wanted to construct a plasmid DNA which is coding for IL-12 (plasmid phIL12), and perform all the necessary testing and prepare the documentation for its clinical testing in the treatment of skin tumours. The SmartGene.si consortium comprises partners from academia and industry. In the project it was necessary to prepare the plasmid according to the European Medicinal Agency (EMA) recommendations. For the application for the study approval submitted to the Agency for Medical Products and Medical Devices of the Republic of Slovenia (JAZMP), it was necessary to perform pharmacological, pharmacokinetic, and efficiency testing of phIL12. Thereafter, we had to develop the process and the facility, and prepare the drug.
      During the last three years, we have achieved all the goals and obtained the approval of the JAZMP for clinical testing of the product phIL12 in humans. We also obtained the approval of the National Ethics Committee. Currently, we are testing phIL-12 in a Phase I clinical protocol on head and neck skin tumours, with the aim to test the safety and feasibility of intratumoral gene electrotransfer of the plasmid phIL12. Another goal of the study is to determine a suitable dose of plasmid that could be used in future studies as adjuvant treatment to ablative therapies such as radiotherapy or electrochemotherapy.
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
  • Watch & Wait following total neoadjuvant therapy of rectal cancer

    • Authors: Anja Meden Boltežar, Franc Anderluh, Vaneja Velenik
      Pages: 22 - 26
      Abstract: Modern standardized treatment of locally advanced rectal cancer (LARC) consists of preoperative chemoradiotherapy (CTRT), operative resection with total mesorectal excision (TME), followed by postoperative chemotherapy (CT) in selected patients. With escalated intensity of preoperative treatment, there was a sig-nificant increase in pathological (pCR) and clinical complete responses (cCR). In carefully selected patients with cCR, close monitoring – watch & wait approach (W&W) instead of surgical treatment is possible. Survival of only monitored patients is not worse in comparison with operated patients, but with the addition of avoiding surgical treatment-related mortality and postoperative complications. In Slovenia, the W&W approach is included in the latest national recommendations for the treatment of colon and rectal cancer. Despite the many benefits of the W&W approach, a risk of recurrence and distant metastasizing still remains. Careful selection of patients is crucial for a favourable treatment outcome. The main problem is cCR assessment subjectivity. This paper describes the case of a patient with LARC who was treated with preoperative CTRT after cCR. The patient was treated with a W&W approach. Two years after beginning treatment, the disease had progressed, and the patient later died.
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
  • Recommendations for the dental management of adult patients with head and
           neck cancer in Slovenia treated with radiation therapy

    • Authors: Aleš Fidler, Aleksander Aničin, Vojko Didanović, Tadej Dovšak, Boris Gašpirc, Aleš Grošelj, Andrej Kansky, Matic Koren, Jana Krapež, Hojka Kuralt, Marko Kuralt, Boštjan Lanišnik, Romana Mance Kristan, Jošt Pavčič, Luka Prodnik, Peter Pukl, Tadej Ostrc, Milan Kuhar, Eva Skalerič, Robert Šifrer, Valerija Skopec, Primož Strojan
      Pages: 28 - 32
      Abstract: Recommendations for the dental treatment of patients with head and neck cancer (HNC) in Slovenia treated with radiation follow the recommendations and guidelines of the Royal College of Surgeons of England created in association with the British Society for Disability and Oral Health, the Recommendations for the treatment of patients with head and neck cancer in Slovenia and at the same time consider the existing capabilities of the Slovenian health care system. The recommendations aim to prevent or reduce complications in the oral cavity due to radiation therapy. They define the dental care before, during and after radiation therapy at all three levels of dental care, which ensures the timeliness and accessibility of dental care. The recommendations represent a unified opinion of all stakeholders in the field of dental treatment of HNC patients in the country.
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
  • Reccomendations for diagnosis and treatment of patients with malignant
           lymphoma

    • Authors: Barbara Jezeršek Novaković, Lučka Boltežar, Gordana Gašljevič, Biljana Grčar Kuzmanov, Monika Jagodic, Tanja Južnič Šetina, Veronika Kloboves-Prevodnik, Gregor Kos, Milica Miljković, Jana Pahole, Samo Rožman, Urška Rugelj, Marija Skoblar Vidmar, Uroš Smrdel, Daniela Štrbac, Miha Toplak, Lorna Zadravec Zaletel, Mateja Dolenc Voljč
      Pages: 34 - 75
      Abstract: no abstract
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
  • Updated recommendations for the diagnosis and treatment of differentiated
           thyroid cancer

    • Authors: Nikola Bešić, Alenka Grošel, Andraž Perhavec, Andrej Doma, Andreja Schwarzbartl-Pevec, Andreja Klevišar Ivančič, Andrej Vogrin, Barbara Vidergar-Kralj, Barbara Gazić, Barbara Perić, Blaž Krhin, Cvetka Grašič Kuhar, Edvard Pirnat, Ivana Žagar, Jerca Blazina, Katarina Zevnik, Katica Bajuk Studen, Katja Zaletel, Margareta Strojan Fležar, Marko Hočevar, Marko Kokalj, Marta Dremelj, Nebojša Glumac, Olga Blatnik, Simona Gaberšček, Snežana Pavlović Đokić, Ulrika Klopčič, Veronika Kloboves-Prevodnik, Zorica Čekić
      Pages: 76 - 106
      Abstract: no abstract
      PubDate: 2022-05-11
      Issue No: Vol. 26, No. 1 (2022)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.200.171.74
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-